EXICURE INC

Exicure has accepted the resignation of Jung Kyu Ham, expanded the board from five to six directors, and appointed Jin Young Go and Eui Seok Han effective immediately as Class-III directors. The board confirms that Eui Seok Han meets NASDAQ requirements as an independent director and that a majority of the board remains independent. The board confirmed the audit committee and established a compensation committee; the company is reviewing strategic alternatives following a restructuring. The stock has fallen sharply year to date (−68.75%) and currently trades at around $2.20 with a market capitalization of about $15.3 million. » Más en de.investing.com

Sangjin Yeo resigned his mandate on Exicure’s board of directors and its audit committee effective last Friday. The company said the resignation was not due to disagreements over business operations, policies or practices. No information was given on a replacement or changes to the committees. » Más en de.investing.com

Exicure has accepted the resignations of CEO Andy Yoo and CFO Seung Ik Baik effective Feb. 9 and appointed three new directors—Jung Kyu Ham, Jung Soo Kim and Gyeung Seog Cheon; successors for CEO and CFO have not yet been named. The company, with a market capitalization of about USD 27.8 million, has seen its share price fall by more than 20% year-to-date. Baik will receive a severance payment of USD 150,000; the new directors will each receive USD 20,000 in annual compensation. In parallel, Exicure reports progress in Phase 2 clinical trials (Burixafor: ~90% achieving the primary endpoint) and the internal repayment of convertible notes totaling USD 3.1 million. » Más en de.investing.com